This question often arises among competitive athletes or individuals undergoing routine drug screening
Masiewicz, P., Brzostek, A., Wolaski, M., Dziadek, J
Likewise, this implicates high effectiveness (i.e., BPC 157 therapy is effective in the 10 g10 ng/kg range)
The consistent demonstration of therapeutic efficacy goes across the occluded vessel, peripheral and/or central, and similarly noxious procedures, as well as various damaging agents applications and a multitude of targets involved
As of April 2026, the BPC-157 FDA approval status remains what it has been for the last two decades: no finished-drug approval, no active Investigational New Drug (IND) application, and no FDA-registered human clinical trials